Cellectis S.A. (CLLS)
NASDAQ: CLLS · Real-Time Price · USD
2.900
-0.090 (-3.01%)
At close: Jul 13, 2026, 4:00 PM EDT
2.774
-0.126 (-4.33%)
Pre-market: Jul 14, 2026, 8:02 AM EDT
Cellectis Revenue
Cellectis had revenue of $7.55M in the quarter ending March 31, 2026, a decrease of -37.25%. This brings the company's revenue in the last twelve months to $75.11M, up 37.20% year-over-year. In the year 2025, Cellectis had annual revenue of $79.59M with 61.72% growth.
Revenue (ttm)
$75.11M
Revenue Growth
+37.20%
P/S Ratio
2.80
Revenue / Employee
$328,000
Employees
229
Market Cap
210.41M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 79.59M | 30.38M | 61.72% |
| Dec 31, 2024 | 49.22M | 40.02M | 435.37% |
| Dec 31, 2023 | 9.19M | -16.53M | -64.26% |
| Dec 31, 2022 | 25.72M | -12.87M | -33.35% |
| Dec 31, 2021 | 38.60M | -20.97M | -35.20% |
| Dec 31, 2020 | 59.56M | 36.57M | 159.09% |
| Dec 31, 2019 | 22.99M | 1.56M | 7.27% |
| Dec 31, 2018 | 21.43M | -12.28M | -36.43% |
| Dec 31, 2017 | 33.72M | -22.73M | -40.27% |
| Dec 31, 2016 | 56.45M | -6.12M | -9.78% |
| Dec 31, 2015 | 62.57M | 30.56M | 95.47% |
| Dec 31, 2014 | 32.01M | 14.51M | 82.92% |
| Dec 31, 2013 | 17.50M | -10.25M | -36.93% |
| Dec 31, 2012 | 27.74M | 7.04M | 34.00% |
| Dec 31, 2011 | 20.70M | -248.60K | -1.19% |
| Dec 31, 2010 | 20.95M | 6.11M | 41.19% |
| Dec 31, 2009 | 14.84M | -2.65M | -15.16% |
| Dec 31, 2008 | 17.49M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Codexis | 78.09M |
| Compugen | 72.66M |
| Precision BioSciences | 45.07M |
| Atrium Therapeutics | 36.68M |
| Voyager Therapeutics | 36.49M |
| Whitehawk Therapeutics | 7.15M |
| Camp4 Therapeutics | 3.93M |
| Korro Bio | 3.84M |
CLLS News
- 18 days ago - Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026 - GlobeNewsWire
- 4 weeks ago - Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress - GlobeNewsWire
- 4 weeks ago - Cellectis Slides: FY 2026 - Filings
- 4 weeks ago - Cellectis (CLLS) Receives FDA RMAT Designation for CAR-T Therapy, Shares Rise - GuruFocus
- 4 weeks ago - Cellectis (CLLS) Achieves RMAT Designation for CAR-T Therapy - GuruFocus
- 4 weeks ago - Cellectis granted RMAT designation for lasmecabtagene timgedleucel from FDA - TheFly
- 4 weeks ago - Cellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a Pivotal Trial for Patients with r/r B-ALL - GlobeNewsWire
- 5 weeks ago - Monthly information on share capital and company voting rights - GlobeNewsWire